Kancera Valuation
Is KAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of KAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate KAN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate KAN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KAN?
Key metric: As KAN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is KAN's PB Ratio? | |
|---|---|
| PB Ratio | 1.6x |
| Book | SEK 83.00m |
| Market Cap | SEK 130.64m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does KAN's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 59.1x | ||
ACTI Active Biotech | 224.9x | 62.1% | SEK 314.9m |
LIPUM Lipum | 7.6x | -22.2% | SEK 362.7m |
ABLI Abliva | 3.2x | -17.6% | SEK 217.6m |
SCOL Scandion Oncology | 0.5x | 69.7% | SEK 17.5m |
KAN Kancera | 1.6x | 47.8% | SEK 130.6m |
Price-To-Book vs Peers: KAN is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (59.1x).
Price to Book Ratio vs Industry
How does KAN's PB Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: KAN is good value based on its Price-To-Book Ratio (1.6x) compared to the Swedish Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is KAN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate KAN's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
AstraZeneca
UK£154.5b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£1,413.50
7D
-1.8%
1Y
4.5%
PMD Device Solutions
SEK 36.3m
A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.
PMDS
SEK 1.28
7D
-14.7%
1Y
n/a
Swedish Orphan Biovitrum
SEK 99.5b
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
SOBI
SEK 290.60
7D
-12.4%
1Y
15.7%